A
Arsime Demjaha
Researcher at King's College London
Publications - 58
Citations - 2780
Arsime Demjaha is an academic researcher from King's College London. The author has contributed to research in topics: Psychosis & Schizophrenia. The author has an hindex of 20, co-authored 49 publications receiving 2215 citations. Previous affiliations of Arsime Demjaha include HealthPartners & South London and Maudsley NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia
TL;DR: In some patients with schizophrenia, antipsychotic treatment may be ineffective because they do not exhibit the elevation in dopamine synthesis capacity that is classically associated with the disorder; this may reflect a different underlying pathophysiology or a differential effect of antipsychotics.
Journal ArticleDOI
Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.
Arsime Demjaha,Alice Egerton,Robin M. Murray,Shitij Kapur,Oliver D. Howes,James M. Stone,Philip McGuire +6 more
Journal ArticleDOI
Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses
John Lally,Olesya Ajnakina,M. Di Forti,Antonella Trotta,Arsime Demjaha,Anna Kolliakou,Valeria Mondelli,T. Reis Marques,Carmine M. Pariante,Paola Dazzan,S. S. Shergil,Oliver D. Howes,Anthony S. David,James H. MacCabe,Fiona Gaughran,Robin M. Murray +15 more
TL;DR: For the majority of the TR group, antipsychotic TR is present from illness onset, necessitating increased consideration for the earlier use of clozapine.
Journal ArticleDOI
Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations.
Jolanta Zanelli,Abraham Reichenberg,Kevin Morgan,Paul Fearon,Eugenia Kravariti,Paola Dazzan,Craig Morgan,Caroline Zanelli,Arsime Demjaha,Peter B. Jones,Gillian A. Doody,Shitij Kapur,Robin M. Murray +12 more
TL;DR: Early in their course, cognitive deficits are present in all psychotic disorders but are most severe and pervasive in schizophrenia and least pervasive in bipolar disorder and mania.
Journal ArticleDOI
Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors.
Arsime Demjaha,Julia Lappin,Daniel Stahl,Maxine X. Patel,James H. MacCabe,Oliver D. Howes,Margaret Heslin,Ulrich Reininghaus,Kim Donoghue,Ben Lomas,Monica Charalambides,Adanna Onyejiaka,Paul Fearon,Peter B. Jones,Gillian A. Doody,Craig Morgan,Paola Dazzan,Robin M. Murray +17 more
TL;DR: The striking majority of treatment-resistant patients do not respond to first-line antipsychotic treatment even at time of FEP, and Clinicians must be alert to this subgroup of patients and consider clozapine treatment as early as possible during the first presentation of psychosis.